Join the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationThe HRA community were asked to complete a diversity and inclusion survey. The results help build a picture of who HRA's members are, help them understand who isn’t part of their community, and help them to take action so that members better reflect the diversity of society.
5th November 2024
The European Medicines Agency (EMA) is hosting an online event to launch the revised guideline on good pharmacovigilance practices (GVP) Module XVI and its Addendum II. The event will provide an overview of how stakeholder comments from the public consultation on these documents have been addressed. This will be followed by a questions and answers session for answering audience questions.
Co-authored by EMA and published in the Clinical Pharmacology & Therapeutics journal.
The eClinical Forum is releasing this version (V2023.3PR) as a service to the eClinical Community.
This reflection paper was co-developed by the European Medicines Agency, the United States of America's (USA) Food and Drug Administration (FDA), and Health Canada and adopted in June 2024 by the Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Assembly.
10 new medicines recommended for approval; another 11 medicines recommended for extension of their therapeutic indications
Draft Guidance Released
Draft Guidance Released
The U.S. Food and Drug Administration is advancing its mission of ensuring the public has access to accurate, up-to-date science-based information to inform decisions about FDA-regulated medical products to maintain and improve their health.